Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel
NASDAQ:NBTX

Nanobiotix H1 2026 Earnings Report

Nanobiotix logo
$38.80 -1.20 (-3.00%)
As of 09/4/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

Nanobiotix EPS Results

Actual EPS
N/A
Consensus EPS
-$0.15
Beat/Miss
N/A
One Year Ago EPS
N/A

Nanobiotix Revenue Results

Actual Revenue
N/A
Expected Revenue
$27.25 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nanobiotix Announcement Details

Quarter
H1 2026
Date
9/29/2026
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Nanobiotix Earnings Headlines

Nanobiotix (NASDAQ:NBTX) Shares Gap Up - Here's Why
September 4 at 4:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003236
Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX) Receives Average Rating of "Moderate Buy" from Analysts
September 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30996109
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
September 5 at 1:00 AM  |  Profits Run (Ad)
Voting Rights and Shares Capital of the Company
August 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3350883/0/en/voting-rights-and-shares-capital-of-the-company.html
Nanobiotix SA Sponsored ADR
August 12, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/NBTX
Voting Rights and Shares Capital of the Company
July 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/30/3336443/0/en/voting-rights-and-shares-capital-of-the-company.html
See More Nanobiotix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nanobiotix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nanobiotix and other key companies, straight to your email.

About Nanobiotix

Nanobiotix (NASDAQ:NBTX) is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma. The company is actively expanding its global footprint with ongoing trials in the United States, Asia, and other regions. Partnerships and collaborations with academic institutions and pharmaceutical companies support the clinical development and potential commercialization of its lead candidate. In addition to NBTXR3, Nanobiotix continues to explore next-generation nanotherapies and combination strategies aimed at enhancing standard oncology protocols.

Founded in 2003 by Dr. Laurent Levy and a team of researchers, Nanobiotix combines expertise in physics, chemistry and oncology to address unmet needs in cancer care. The company maintains R&D facilities in Europe and the United States and is led by Dr. Levy, who serves as Chief Executive Officer. Through its science-driven approach, Nanobiotix seeks to deliver safer, more effective treatment options for patients worldwide and to transform the way radiotherapy is applied in solid tumor oncology.

View Nanobiotix Profile
Earnings Tools